Caricamento...
What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
The introduction of biosimilars of biological agents for which the patents and exclusivity periods have expired is an attractive way of reducing healthcare spending through price competition with the reference product. In oncology, biosimilars of growth factors for supportive therapy were the pionee...
Salvato in:
| Pubblicato in: | Breast Care (Basel) |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
S. Karger GmbH
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6465746/ https://ncbi.nlm.nih.gov/pubmed/31019437 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000496834 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|